Idiopathic Inflammatory Myopathies · Internal Medicine

Internal Medicine · Clinical Specialties

How it begins

Grupo heterogéneo de enfermedades autoinmunes sistémicas que afectan predominantemente el músculo esquelético. Análisis exhaustivo de la clasificación contemporánea, fisiopatología, perfil de autoanticuerpos, manifestaciones clínicas, criterios diagnósticos EULAR/ACR 2017 y estrategia terapéutica basada en evidencia.

What it covers

1. · Idiopathic Inflammatory Myopathies
2. Definition, Classification and Nomenclature
3. Epidemiology
4. Molecular and Immunological Physiopathology
5. · 3.1 Polymyositis — Targeted CD8+ T Cytotoxicity
6. · 3.2 Dermatomyositis — Complement-Mediated Vasculopathy
7. · 3.3 Inclusion Body Myositis (IBM) — The Enigma of Inflammation and Degeneration
8. · 3.4 Autoimmune Necrotizing Myopathy (IMNM) — Direct Pathogenic Antibodies
9. Autoantibody Profile — Serological Classification System
10. · 4.1 Myositis Specific Antibodies (MSA)
11. · 4.2 Myositis Associated Antibodies (MAA)
12. Clinical Manifestations
13. · 5.1 Muscle Commitment
14. · 5.2 Cutaneous Manifestations — Exclusive to Dermatomyositis
15. · 5.3 Interstitial Lung Disease (ILD) — The Deadliest Complication
16. · 5.4 Cardiac Compromise
17. · 5.5 Joint Commitment and Other Manifestations
18. · 5.6 Antisynthetase Syndrome (SAS) — Complete Clinical Phenotype
19. Diagnosis — EULAR/ACR 2017 Criteria and Comprehensive Evaluation
20. · 6.1 Laboratory Evaluation
21. · 6.2 Imaging and Electromyography
22. · 6.3 Muscle Biopsy — The Diagnostic Standard
23. Therapeutic Strategy
24. · 7.1 Corticosteroids — Universal First Line (except IBM)
25. · 7.2 Steroid Sparing (Background Immunosuppressants)
26. · 7.3 Biological Therapies and Small Molecules
27. · 7.4 IBM Treatment — The Great Challenge
28. Association with Neoplasias — Oncological Screening
29. · 8.1 Antibody Risk
30. Differential Diagnosis
31. Forecasting, Follow-up and Monitoring
32. · 10.1 Prognostic Factors
33. · 10.2 Monitoring Plan